Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2026-06-04 Proxy Solicitation & In…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
关于召开2025年度股东会通知的公告
Proxy Solicitation & Information Statement Classification · 91% confidence The document is a formal announcement (公告) of the 2025 Annual General Meeting of Kangzhi Pharma, detailing meeting date, time, location, agenda items (proposals), eligibility, registration, voting methods (onsite and online), and includes proxy authorization forms. It is sent to shareholders to inform them of the meeting and solicit votes on the listed proposals. This matches the definition of a Proxy Solicitation & Information Statement (PSI).
2026-06-04 Chinese
关于实际控制人部分股份质押的公告
Regulatory Filings Classification · 90% confidence The document is an announcement by 康芝药业股份有限公司 detailing the actual controller’s partial share pledge, including pledge quantities, proportions, terms, and related financial details. It is not a financial report (e.g., annual or interim report), not a proxy or voting results, and not a share issuance or repurchase. Pledges by a controlling shareholder do not fit into categories like share issue/capital change (SHA), transaction in own shares (POS), or director’s dealing (DIRS). Therefore, this is a general regulatory announcement/disclosure that does not fit any other specific category, making “Regulatory Filings” (RNS) the appropriate classification.
2026-06-01 Chinese
关于收到注射用头孢他啶他唑巴坦钠（3 ：1）临床试验批准通知书的公告
Regulatory Filings Classification · 92% confidence The document is a corporate announcement by 康芝药业 reporting that it received a clinical trial approval notice from the National Medical Products Administration. It is not a financial report, earnings release, board change, M&A, share transaction, proxy, dividend, or any other specialized category. It is a general regulatory announcement of approval for drug clinical trials, fitting the fallback “Regulatory Filings (RNS)” category.
2026-05-26 Chinese
关于公司获得药品注册证书的公告
Regulatory Filings Classification · 90% confidence The document is a corporate announcement by Honz Pharma (康芝药业) informing investors that it has received a drug registration certificate from the National Medical Products Administration. It does not contain financial statements, management or board changes, dividends, share issues, or detailed ESG or legal information. It is a general regulatory/compliance announcement and thus falls under the fallback category for miscellaneous regulatory filings (RNS).
2026-05-19 Chinese
关于参加海南辖区上市公司2025年年报业绩说明会暨投资者网上集体接待日活动的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the company's participation in an investor meeting focused on the 2025 annual report performance explanation and investor interaction. It mentions the event details, including date, time, and topics to be discussed such as 2025 annual performance, governance, strategy, financing plans, and sustainability. The document does not contain the actual annual report or financial data but rather informs about the company's involvement in a performance explanation meeting. This fits the definition of an Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position, conducted in a meeting format. The document length is short and it is not the report itself, nor is it a simple announcement of report publication. Therefore, the best classification is Investor Presentation (IP).
2026-05-07 Chinese
互动易平台信息发布及回复内部审核制度
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '互动易平台信息发布及回复内部审核制度' (Internal Review System for Information Release and Reply on Interactive Platform) issued by 康芝药业股份有限公司. It outlines rules and procedures for managing investor communications on an interactive platform, emphasizing compliance with laws, fairness, and information disclosure standards. There are no financial statements, earnings data, or regulatory filings such as audit reports or annual reports. The document is a governance-related internal policy approved by the board, focusing on communication and disclosure practices rather than financial results or corporate actions. Therefore, it fits best under Governance Information (CGR). The document length is 2160 characters, which is short and not a report publication announcement. Hence, the classification is CGR with high confidence.
2025-11-21 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.